{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:13:43Z","timestamp":1791335623270,"version":"4.3.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.lungcan.2012.06.011","type":"journal-article","created":{"date-parts":[[2012,7,23]],"date-time":"2012-07-23T17:16:20Z","timestamp":1343063780000},"page":"76-80","source":"Crossref","is-referenced-by-count":47,"title":["Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium"],"prefix":"10.1016","volume":"78","clinical-trial-number":[{"clinical-trial-number":"nct00309946","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Nicholas P.","family":"Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rangesh","family":"Kunnavakkam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Leighl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Gandara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Koczywas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara J.","family":"Gitlitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edem","family":"Agamah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachdev P.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter M.","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everett E.","family":"Vokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedy L.","family":"Kindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2012.06.011_bib0005","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1055\/s-0031-1272874","article-title":"Update on malignant pleural mesothelioma","volume":"32","author":"Campbell","year":"2011","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.lungcan.2012.06.011_bib0010","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.06.011_bib0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2010.12.004","article-title":"Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma","volume":"72","author":"Ceresoli","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2012.06.011_bib0020","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.06.011_bib0025","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2007.01.006","article-title":"Vascular endothelial growth factor (VEGF) signaling in tumor progression","volume":"62","author":"Roskoski","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.lungcan.2012.06.011_bib0030","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/1477-3163.77274","article-title":"Role of protein kinase C beta and vascular endothelial growth factor receptor in malignant pleural mesothelioma: therapeutic implications and the usefulness of Caenorhabditis elegans model organism","volume":"10","author":"Loganathan","year":"2011","journal-title":"J Carcinog"},{"key":"10.1016\/j.lungcan.2012.06.011_bib0035","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.06.011_bib0040","article-title":"The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin\/gemcitabine","author":"Kao","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2012.06.011_bib0045","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1158\/0008-5472.CAN-04-4409","article-title":"AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer","volume":"65","author":"Wedge","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2012.06.011_bib0050","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1200\/JCO.2006.07.2066","article-title":"Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors","volume":"25","author":"Drevs","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.06.011_bib0055","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.lungcan.2012.06.011_bib0060","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2012.06.011_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.lungcan.2012.06.011_bib0070","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.lungcan.2012.06.011_bib0075","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.semnephrol.2010.09.007","article-title":"Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker","volume":"30","author":"Robinson","year":"2010","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.lungcan.2012.06.011_bib0080","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/annonc\/mdn729","article-title":"Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma","volume":"20","author":"Bono","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2012.06.011_bib0085","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1200\/JCO.2008.16.1612","article-title":"Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100","volume":"26","author":"Schneider","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.06.011_bib0090","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/annonc\/mdn637","article-title":"Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab","volume":"20","author":"Scartozzi","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2012.06.011_bib0095","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1200\/JCO.2009.25.4482","article-title":"Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599","volume":"28","author":"Dahlberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.06.011_bib0100","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/JTO.0b013e318229586e","article-title":"Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509","volume":"6","author":"Garland","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2012.06.011_bib0105","first-page":"1359","article-title":"SU5416 in malignant mesothelioma: a University of Chicago Phase II Consortium Study","volume":"20","author":"Kindler","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.06.011_bib0110","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.lungcan.2004.10.005","article-title":"Thalidomide in patients with malignant pleural mesothelioma","volume":"48","author":"Baas","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2012.06.011_bib0115","doi-asserted-by":"crossref","first-page":"7036","DOI":"10.1200\/jco.2010.28.15_suppl.7036","article-title":"Final results of a phase II trial of sunitinib as second-line therapy in malignant pleural mesothelioma","volume":"28","author":"Nowak","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2012.06.011_bib0120","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","article-title":"A phase II study of sorafenib in malignant mesothelioma: results of cancer and leukemia group B 30307","volume":"5","author":"Dubey","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2012.06.011_bib0125","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.lungcan.2011.11.014","article-title":"Vatalanib in malignant mesothelioma: a Phase II trial by the cancer and leukemia group b (CALGB 30107)","volume":"76","author":"Jahan","year":"2012","journal-title":"Lung Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500212004266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500212004266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T00:02:14Z","timestamp":1542844934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500212004266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0169500212004266"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2012.06.011","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}